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Abstract: In 2015, the International Federation of Gynecology and Obstetrics established the
prevention of exposures to environmental reprotoxic substances as a priority for health professionals.
However, available information about reproductive hazards is voluminous, dispersed, and complex,
and this is a severe limitation for physicians to incorporate the prevention of environmental
exposure into standard preventive care. One difficulty frequently cited by physicians is the lack
of evidence-based information. The objective of our study was to identify a list of environmental
chemical hazards to reproduction. We used lists present in relevant regulations or included in
scientific reports or databases to identify reproductive hazards. The reproductive hazards were
prioritized according to the strength of evidence concerning their impact on fertility or development
of the offspring. We identified 1251 reproductive hazards. Our prioritization approach resulted
in a high-priority classification for 462 risk factors belonging to the following eight classes: drugs
(n = 206), metals (n = 116), pesticides (n = 38), organic solvents (n = 27), synthesizing and/or
processing agents in industrial processes (n = 23), phthalates (n = 13), perfluorinated compounds
(n = 13), and other compounds (n = 26). Despite the limitations of this work, the generated lists
constitute a useful working basis to put in place innovative environmental preventive measures
according to the principle of evidence-based medicine.
Keywords: reproductive health; perinatal care; preventative medicine; environmental exposure;
occupational exposure; chemical hazards
1. Introduction
A growing body of literature demonstrates the adverse effects of environmental exposure on
reproductive health, including fertility, pregnancy, and postnatal development [1]. Occupational
and non-occupational exposure to contaminants is now identified to be responsible for adverse
outcomes. For example, exposure to alcohol, tobacco products, polychlorobiphenyls (PCBs), phthalates,
radiation, or heat have been linked to decreased sperm concentration or semen quality [2]. Exposure
to air-borne pollutants, lead, environmental tobacco smoke, pesticides, or organic solvents have
been related to adverse birth outcomes [3,4]. There is consistent evidence for an association between
exposure to heavy metals and polychlorinated biphenyls (PCBs) and the impairment of the postnatal
neurodevelopment [5].
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The accumulating evidence prompted the International Federation of Gynecology and Obstetrics
(FIGO) to establish the prevention of exposures to reprotoxic substances as a priority for obstetricians,
gynecologists, midwives, and the other perinatal health professionals in 2015. FIGO recommended
that reproductive health providers learn about toxic chemicals and other harmful environmental
exposures and take environmental histories during visits to educate patients about how to avoid toxic
environmental chemicals [1].
Perinatal health providers do not generally ask patients about their environmental exposure
except for alcohol, tobacco, and other drugs. Indeed, a national survey in the United States found that
less than 20% of obstetricians routinely interview their patients about their environmental exposure [6].
These results are consistent with those of a French study, which found that few obstetricians, midwives,
or general practitioners ask and advise women about their chemical exposure [7].
Although health professionals recognize the potential impact of the environment on reproductive
health [8], they cite numerous barriers to counseling patients, one of which is the lack of evidence-based
information about the risks [6,7]. Perinatal health professionals require science-based guidelines and
resources about environmental reproductive hazards before they can develop such prevention-oriented
actions [6].
Indeed, the available information is voluminous, dispersed, and complex, and its quality varies
widely, depending on the data source. Reviews of the available epidemiological or toxicological data
published in scientific journals can provide data on reproductive risk factors [2–5,9]. Some American
and European regulations frame the classification of toxic chemicals to properly identify and
communicate the hazards of substances, including reproductive impairments [10]. In addition,
national programs and scientific agency publications tend to provide synthesized information about
occupational and non-occupational hazards to human reproductive health [11–14].
The main objective of this study was to identify chemical hazards to reproductive health from
various data sources. The secondary objective was to prioritize them according to the weight of
the evidence.
2. Methods
2.1. Identification of Chemical Reproductive Hazards
Environmental reproductive hazards include biological hazards, toxic chemicals, physical agents,
and biomechanical or organizational demands that could harm sexual function, fertility, or in utero or
postnatal development of the offspring. Here, we focused only on chemicals. Indeed, clinicians are
generally familiar with the biological and physical risks. We also chose to exclude medical treatments
that cannot be considered to be environmental exposures. Therefore, we included drugs when they
could lead to occupational exposures in medical or research environments.
We identified environmental reproductive hazards using lists present in relevant regulations,
scientific reports, or databases coming from recognized health agencies. All such classifications are
based only on the intrinsic hazard of the substances and do not integrate the likelihood of exposure or
the idea of risk.
We selected two regulatory texts: the European regulation on the classification, labeling, and
packaging of substances and mixtures (CLP) [10] and Proposition 65, supervised by the Office of
Environmental Health Hazard Assessment (OEHHA) of California [15].
2.1.1. The CLP Regulation
One of the main aims of the CLP regulation is to determine whether a substance or mixture
displays properties that lead to a hazardous classification. The text distinguishes 10 hazard classes,
including two especially relevant to evaluating reproductive hazards:
• The “germ cell mutagenicity” class, which is primarily concerned with substances that may cause
mutations in the germ cells of humans that can be transmitted to their progeny.
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• The “reproductive toxicity” class, which includes adverse effects on sexual function and fertility
in adult males and females, as well as developmental toxicity in their offspring.
Within these two classes, chemicals are divided into three categories based on the standard of
proof concerning their adverse health effects.
Concerning “reproductive toxicity”, reliable evidence of an adverse effect in humans leads to a
category 1A classification “known human reproductive toxicant”. Less rigorous data from human or
animal studies result in a category 1B classification “presumed human reproductive toxicant”. Finally,
insufficient data from human or animal studies to place the substance in category 1 result in a category
2 classification “suspected human reproductive toxicant”. We chose to select the three categories for
our identification of reproductive risk factors.
Concerning “germ cell mutagenicity”, the classification in category 1A is based on positive
epidemiological studies, whereas category 1B and 2 are principally based on positive in vivo
mutagenicity studies or even in vitro studies. We chose to consider only categories 1A and 1B to
guarantee a sufficient level of evidence.
Under the CLP Regulation, a substance must be classified according to harmonized classifications
listed in Annex VI in order to ensure an adequate risk management in the European Union (EU).
When a substance has no harmonized classification in Annex VI to the CLP but presents hazardous
properties, it must be self-classified by the manufacturer or importer according to available information.
In our work, we only considered the substances covered by the harmonized classification and labeling
regulation registered in Annex VI to the CLP regulation in order to be as rigorous as possible concerning
the scientific evidence. Hence, we excluded substances concerned by self-classification processes that
were not subjected to a consensus [10].
2.1.2. Proposition 65
Proposition 65, also known as the Safe Drinking Water and Toxic Enforcement Act of 1986,
was created to inform Californians about their exposures to chemicals, and it established a list of
substances known to cause adverse health effects, including cancers, birth defects, or other reproductive
harm [15]. This classification incorporates chemicals identified by: 1) the American Labor Code, 2)
two independent committees of scientific and health experts (the Carcinogen Identification Committee
and the Developmental and Reproductive Toxicant Identification Committee), 3) authoritative bodies
(the United States Environmental Protection Agency (U.S. EPA), U.S. Food and Drug Administration
(U.S. FDA), National Institute for Occupational Safety and Health (NIOSH), the National Toxicology
Program (NTP) of the US Department of Health and Human Services, and the International Agency
for Research on Cancer (IARC)), and 4) agencies of the state or federal government. The list is
reviewed at least annually. This classification does not prioritize the hazard depending on the scientific
evidence [15].
We also incorporated four lists proposed by recognized health agencies or research institutions to
complement these regulatory sources.
2.1.3. The Monographs Published by the National Toxicology Program (NTP)
The NTP Center for the Evaluation of Risks to Human Reproduction (NTP-CERHR) was
established by the NTP and the National Institute of Environmental Health Sciences (NIEHS), two U.S.
agencies, in 1998 to address the impact of chemical exposure on human reproduction and development.
In 2010, it became the NTP Office of Health Assessment and Translation (OHAT). The products of
this approach are monographs on chemicals, including an expert panel report and public comments.
The reports include information about the weight of evidence regarding each substance’s toxicity on
laboratory animals and/or humans [12]. We chose to select the compounds with “clear evidence” of
reproductive adverse effects.
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2.1.4. The NIOSH List of Drugs
The NIOSH of the Centers for Disease Control and Prevention (CDC) has made a list of hazardous
drugs for health professionals, including those that affect reproductive health. The first list, created in
2004, has been regularly updated (last version in 2016). For each drug, the potential to cause a birth
defect is indicated using the five FDA pregnancy risk categories, established prior to 2015 (A, B, C,
D, or X). Three of these categories indicate a risk to reproductive health: category C includes drugs
for which animal studies have shown an adverse effect on fetuses; category D incorporates drugs for
which there is positive evidence of human fetal risk; and category X includes substances for which
studies in animals or humans have demonstrated abnormalities and/or a human fetal risk [11].
2.1.5. The DEMETER Database
The DEMETER (Documents pour l’Évaluation Médicale des produits Toxiques vis-à-vis de
la Reproduction) database was developed by the French National Research and Safety Institute
for the Prevention of Occupational Accidents and Diseases (INRS) to summarize information
about reproductive hazards. The database incorporates information sheets written by toxicology
experts based on bibliographic studies. Human and animal data are differentiated. The weight of
evidence concerning adverse outcomes on reproductive health is specified for each chemical [13].
We only considered substances with limited or sufficient evidence from studies in humans and/or
experimental animals.
2.1.6. The Priority List of Chemicals Developed within the EU-Strategy for Endocrine Disrupters (EDs)
In 1999, the Commission adopted the ‘Community strategy for Eds’, which included the
establishment of a priority list of substances. Three reports were published between 2000 and
2007 [14,16,17].
Each chemical has been assigned to a category related to the strength of evidence for endocrine
disruption: category 1—evidence of endocrine disrupting activity in at least one species using
intact animals, category 2—at least some in vitro evidence of biological activity related to endocrine
disruption, and category 3—no evidence of endocrine disrupting activity or no data available [14].
We considered only category 1 and selected the substances found on the other selected lists, as these
lists are not specific for reproductive hazards.
2.2. Prioritization of Environmental Reproductive Hazards
The main objective for identifying reproductive hazards was to help health professionals assess
their patients’ environments to propose appropriate and proportionate prevention-oriented measures.
We chose a pragmatic approach by prioritizing the substances according to the strength of evidence
concerning their reproductive hazards. Our prioritization approach included three categories based on
the quality of the studies used to evaluate the reprotoxic compounds.
• Category 1 included high-priority chemical risk factors for which adverse health effects have been
demonstrated in epidemiological studies or documented in robust animal studies.
• Category 2 included the medium-priority chemical risk factors for which adverse reproductive
outcomes have been observed in human or animal studies (but with results not robust enough to
rise to a category 1 classification) and appeared in more than one classification.
• Category 3 contained low-priority chemical risk factors for which adverse reproductive outcomes
have been observed in human or animal studies or in vitro experiments but appeared in only
one classification.
As mentioned previously, some selected classifications already included a prioritization of the
substances’ intrinsic toxicities (lists from the CLP regulation, the NTP-OHAT monographs, DEMETER
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data sheets, and the NIOSH report). Some other classifications did not do so by default (lists from
Proposition 65 and EDs). We considered the weight of evidence for this last category to be low.
Category 1 included the following:
# Substances or mixtures classified by the CLP Regulation as reproductive toxicants in categories
R1A and R1B.
# Compounds identified in the DEMETER database for which there was sufficient or limited
evidence of adverse health effects in epidemiological studies or sufficient evidence documented
in robust animal studies.
# Toxicants studied by the NTP-OHAT with clear evidence of adverse developmental or
reproductive effects in humans or laboratory animals.
# Substances listed in the report produced by the NIOSH.
Categories 2 and 3 included the following:
# Substances or mixtures classified by the CLP Regulation as reproductive toxicants in category
R2 or as a mutagen in categories 1A or 1B.
# Toxicants registered on the OEHHA list.
# Compounds identified in the DEMETER sheets for which there is sufficient or limited evidence
of adverse health effects in animal studies.
# Toxicants studied by the NTP-OHAT with limited evidence of adverse developmental or
reproductive effects in laboratory animals.
# Chemicals ranked in category 1 on the priority list of chemicals developed within the
EU-Strategy for ED.
We then performed a search and merged duplicates based on the Chemical Abstracts Service
(CAS) registry number and the name of the substance. The chemical families listed in some of our
sources have been broken down into individualized substances recorded in other lists when necessary.
Finally, we removed the EDs that were not included in lists other than that developed within the
EU-Strategy for EDs.
Figure 1 summarizes our method for identifying and prioritizing reproductive risks factors from
existing classifications.
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between the number of substances identified during the first step of our method and the number of 
Figure 1. Method for identifying and prioritizing risk factors. CLP: the European regulation
on the classification, labeling, and packaging of substances and mixtures; NTP-OHAT: National
Toxicology Program Office of Health Assessment and Translation; DEMETER: Documents pour
l’Évaluation Médicale des produits Toxiques vis-à-vis de la Reproduction; NIOSH: National Institute
for Occupational Safety and Health; and ED: Endocrine Disrupters.
3. Results
3.1. Results of the Identification
The extraction of the lists of reproductive hazards from the identified classifications was performed
on December 11, 2017. From the list provided by t e CLP regulation, we identified 27 substances
or mixtures classified in category R1A, 230 classified in category R1B, 143 classified in category
R2, 0 classified in category M1A, a d 427 classified in category M1B. From the Proposition 65 list,
we xtracted 313 chemicals that could cause adverse dev lopmental outcomes r female or male
fertility disorders. Among the monogr phs published by the NTP-OHAT, we identified 12 che icals
with clear evidence of adverse effects on laboratory animals, two substances with limit d evidence of
adverse effects on l boratory animals, and two subst nces with clear evidence of no adverse effects.
From the list established by the NIOSH, we obtained 216 rugs for which studies in animals or humans
have demonstrated an advers effect on the fetus. From th dat sheets of the DEMETER database,
we obtained 38 substanc s with limited or sufficient vidence from studies in humans and/or wit
sufficient evi ence from studies in experimental animals and 44 substan es with limited evidence from
st dies in experimental animals. From th priority list of chemicals d veloped within the EU-Strategy
EDs, we obtained 194 substances.
3.2. Results of the Prioritization
Table 1 shows the results of the identification exercise after matching and merging according
to the CAS number and/or the substance’s name. In some lists, we could observe discrepancies
between the number of substances identified during the first step of our method and the number of
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chemical identified after matching and merging. For instance, we previously identified 313 chemicals
from the Proposition 65 list, whereas we counted 333 substances after the procedure. Proposition
65 listed polybrominated biphenyls and polychlorinated biphenyls without detailing the congeners
belonging to this family, whereas the list of EDs recorded these chemicals individually. In our method,
we considered that all these substances registered on the EDs’ list were also listed in Proposition
65. Therefore, the number of substances identified from Proposition 65 increased after the matching
and merging process. Finally, we observed a total overlap across the sources for 256 substances
(e.g., difference from sum of columns and the line “total of chemicals”).
Table 1 shows the results of the prioritization procedure. As established in our method,
we removed the EDs that did not appear in the classifications other than that generated by the
European Commission. Finally, we classified 462 substances in Category 1, 79 chemicals in Category 2,
and 710 compounds in Category 3. We observed some overlaps across sources within each category.
Proportionally, overlaps were more important in Category 2 than in Category 1 and were null in
Category 3. This is directly linked to our rules of prioritization. Thus, in Category 1, all the 98
substances extracted from Proposition 65 and the 15 chemicals from the EU list of EDs were recorded in
other classifications as well. Almost all the substances studied by the NTP-OHAT were also identified
as harmful by the CLP regulation or the DEMETER Database.
Table 2 shows all the chemicals identified as Category 1 “high-priority chemical risk factors”.
We divided the compounds by eight classes to facilitate the analysis of the results: drugs, metals and
metalloids, pesticides, organic solvents, synthesizing and/or processing agents in industrial processes,
phthalates, perfluorinated compounds, and other compounds. Although only chemicals from Category
1 have been presented in Table 2, supplemental Table S1 including the full list of hazards from all the
categories with their CAS numbers is available on request. For each compound, the lists on which a
substance has been registered are specified.
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List of the reprotoxic substances or
mixtures registered in Annex VI
378 246 31 101
The CLP Regulation
List of the mutagenic substances or
mixtures registered in Annex VI
427 15 8 404
Proposition 65 list 333 98 57 178
Lists established by health
agencies or research
organizations
Monographs published by the
NTP-OHAT 12 10 0 2
The NIOSH List of Antineoplastic
and Other Hazardous Drugs in
Healthcare Settings
205 205 0 0
Priority list of chemicals developed
within the EU-Strategy for Endocrine
Disrupters
70 15 55 0
DEMETER database 82 46 11 25
Total of chemicals 1251 462 79 710
CLP: the European regulation on the classification, labeling, and packaging of substances and mixtures; NTP-OHAT: National Toxicology Program Office of Health Assessment and
Translation; DEMETER: NIOSH: National Institute for Occupational Safety and Health.




Antineoplastic agents (n = 95)
ado-trastuzumab emtansine; altretamine; anastrozole; arsenic trioxide; axitinib; azacitidine; belinostat; bendamustine; bexarotene; bicalutimide; bleomycin; bortezomib;
bosutinib; brentuximab vedotin; busulfan; cabazitaxel; cabozantinib; capecitabine; carboplatin; carfilzomib; carmustine; chlorambucil; cisplatin; cladribine; clofarabine;
crizotinib; cytarabine; dabrafenib; dacarbazine; dactinomycin; dasatinib;decitabine;degarelix; docetaxel; droloxifen; enzalutamide; epirubicin; eribulin; erlotinib;
estramustine; etoposide; everolimus; exemestane; floxuridine; fludarabine; fluorouracil; flutamide; fulvestrant; gemcitabine; gemtuzumab ozogamicin; hydroxyurea;
idarubicin; ifosfamide; imatinib; irinotecan; ixabepilone; letrozole; lomustine; mechlorethamine; melphalan; mercaptopurine; methotrexate; mitomycin; mitotane;
nelarabine; nilotinib; omacetaxin; oxaliplatin; paclitaxel; pazopanib; pemetrexed; pentostatin; pertuzumab; pomalidomide; ponatinib; pralatrexate; regorafenib;
romidepsin; sorafenib; sunitinib; temozolomide; temsirolimus; teniposide; thioguanine; topotecan; toremifene; trametinib; triptorelin; valrubicin; vandetanib;
vemurafenib; vinorelbine; vismodegib; vorinostat;
ziv-aflibercept
Other drugs (n = 111)





abacavir; abiraterone acetate; acitretin; afatinib; alitretinoin; ambrisentan; apomorphine; azathioprine; bosentan; carbamazepine; cetrorelix; chloramphenicol;
choriogonadotropin; cidofovir; clomiphene; clorazepate dipotassium; colchicine; cyclophosphamide (anhydrous); cyclosporine; daunorubicin hydrochloride; deferiprone;
dexrazoxane; diethylstilbestrol (des); dinoprostone; divalproex; doxorubicin hydrochloride (adriamycin); dronedarone; dutasteride; entecavir; ergonovine/methylergo-novine;
eslicarbazepine; estradiol estrogen/progester-one combinations; estrogens, esterified; estrogens, conju-gated; estropipate; finasteride; fingolimod; fluconazole;
fluoxymesterone; fosphenytoin; ganciclovir; ganirelix; gonadotropin, chorionic; goserelin; histrelin acetate; icatibant; leflunomide; lenalidomide; leuprolide acetate; liraglutide;
lomitapide; macitentan; medroxyprogesterone acetate; megestrol acetate; menotropins; methimazole; methyltestosterone; mifepristone; mipomersen; misoprostol;
mitoxantrone hydrochloride; mycophenolate mofetil; mycophenolic acid; nafarelin acetate; nitrous oxide; ospemifene; oxcarbazepine; oxytocin; palifermin; paliperidone;
pamidronate; paroxetine; pasireotide; peginesatide; pentetate calcium triso-dium; phenoxybenzamine; phenytoin; pipobroman; plerixafor; procarbazine hydrochloride;
progestins; raloxifene; rasagiline; ribavirin; riociguat; risperidone; sirolimus; spironolactone; streptozocin (streptozotocin); tacrolimus; tamoxifen citrate; telavancin;
temazepam; teriflunomide; testosterone; thalidomide; tofacitinib; topiramate; tretinoin; ulipristal; uracil mustard; valganciclovir; valproate (valproic acid); vigabatrin;
vinblastine sulfate; vincristine sulfate; voriconazole; warfarin; zidovudine; ziprasidone; zoledronic acid; zonisamide
Metals and metalloids
(n = 116)
Lead and its compounds (n = 15)
lead hexafluorosilicate; silicic acid, lead nickel salt; lead compounds with the exception of those specified elsewhere in the CLP regulation; lead alkyls; lead diazide, lead azide;
lead chromate; lead di(acetate); trilead bis(orthophosphate); lead acetate, basic; lead(II) methanesulphonate; lead sulfochromate yellow; lead chromate molybdate sulfate red;
lead hydrogen arsenate; lead; lead styphnate
Nickel and its compounds (n = 69)
tetracarbonylnickel; nickel dihydroxide; nickel hydroxide; nickel sulfate;
[carbonato(2-)]tetrahydroxytrinickel[µ-[carbonato(2-)-O:O’]] dihydroxy trinickel; carbonic acid, nickel salt; nickel carbonate; nickel dichloride; nitric acid, nickel salt; nickel
dinitrate; slimes and sludges, copper electrolytic refining, decopperised, nickel sulfate; nickel diperchlorate; diammonium nickel bis(sulfate); nickel dipotassium bis(sulfate);
nickel bis(sulfamidate); nickel bis(tetrafluoroborate); formic acid, copper nickel salt; formic acid, nickel salt; nickel diformate; nickel acetate; nickel di(acetate); nickel
dibenzoate; nickel bis(4-cyclohexylbutyrate); nickel(II) stearate; nickel dilactate; nickel(II) octanoate; nickel dibromide; nickel diiodide; nickel difluoride; nickel potassium
fluoride; nickel hexafluorosilicate; nickel selenite; nickel dithiocyanate; nickel dichromate; nickel dichlorate; ethyl hydrogen sulfate, nickel(II) salt; nickel dibromate;
dimethylhexanoic acid nickel salt; (isodecanoato-O)(isononanoato-O)nickel;
(isooctanoato-O)(neodecanoato-O)nickel; nickel bis(isononanoate);
(2-ethylhexanoato-O)(isodecanoato-O)nickel; nickel(II) palmitate;
nickel 3,5-bis(tert-butyl)-4-hydroxybenzoate (1:2); nickel(II) neononanoate;
bis(D-gluconato-O1,O2)nickel; fatty acids, C8-18 and C18-unsatd., nickel salts; nickel(II) neoundecanoate; nickel(II) propionate;2-ethylhexanoic acid, nickel salt; nickel
bis(benzenesulfonate); citric acid, ammonium nickel salt; nickel(II) neodecanoate; nickel(II) isodecanoate;
(isononanoato-O)(neodecanoato-O)nickel; nickel(II) isooctanoate; (isononanoato-O)(isooctanoato-O)nickel; (2-ethylhexanoato-O)(isononanoato-O)nickel; nickel
bis(2-ethylhexanoate); (isodecanoato-O)(isooctanoato-O)nickel; fatty acids, C6-19-branched, nickel salts; nickel(II) trifluoroacetate; citric acid, nickel salt;
(2-ethylhexanoato-O)(neodecanoato-O)nickel; neodecanoic acid, nickel salt; nickel(II) hydrogen citrate; nickel isooctanoate; 2,7-naphthalenedisulfonic acid, nickel(II) salt
Boron and its compounds (n = 13)
perboric acid (H3BO2(O2)), monosodium salt, trihydrate; perboric acid, sodium salt, monohydrate, perboric acid, sodium salt; disodium octaborate tetrahydrate, disodium
octaborate anhydrous; dibutyltin hydrogen borate; boric acid; diboron trioxide; tetraboron disodium heptaoxide, hydrate; orthoboric acid, sodium salt; disodium tetraborate
decahydrate; sodium peroxometaborate; di-sodium tetraborate anhydrous; boric acid; sodium perborate
Other compounds (n = 19)
slimes and sludges, copper electrolyte refining, decopperised; potassium dichromate; ammonium dichromate; sodium dichromate; sodium chromate; cobalt dichloride; cobalt
sulfate; cobalt di(acetate); cobalt dinitrate; cobalt carbonate; gallium arsenide; cadmium fluoride; cadmium chloride; cadmium sulphate; tributyltin compounds; dibutyltin
dichloride;
2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate; dibutyltin dilaurate; mercury and mercury compounds





1,2-dibromo-3-chloropropane; azafenidin; benomyl; binapacryl; brodifacoum; bromadiolone; bromomethane; carbendazim; carbetamide; chlorophacinone; coumatetralyl;
cycloheximide; cyproconazole; difenacoum; difethialone; dinocap; dinoseb; dinoterb; epoxiconazole; etacelasil; flocoumafen; fluazifop-butyl; flumioxazin; flusilazole;
glufosinate ammonium; imidazole; ketoconazole; linuron; nitrofen; quizalofop-p-tefuryl; salts and esters of dinoseb; salts and esters of dinoterb; silafluofen; thiacloprid;
triadimenol; tridemorph; triflumizole; vinclozolin
Organic solvents
(n = 27)
Glycol ether family (n = 11)
1,2-diethoxyethane; 2-methoxyethanol; 2-ethoxyethanol; 1,2-dimethoxyethane;2-methoxypropanol; bis(2-methoxyethyl) ether; 1,2-bis(2-methoxyethoxy)ethane;
2-methoxyethyl acetate; 2-ethoxyethyl acetate; 2-methoxypropyl acetate; methoxyacetic acid
1,2,3-trichloropropane
Other solvents (n = 16)
2,3-epoxypropan-1-ol; 2-butanone; dimethylacetamide; dimethylformamide; ethanol; ethylene glycol; formamide; Hexan-2-one; methanol; methylacetamide;
methylformamide;





1,3-diphenylguanidine; 1-bromopropane; 2-(2-aminoethylamino)ethanol; 2,3-epoxypropyl methacrylate; 2-bromopropane;
2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one; acrylamide; carbon disulphide; chloroform; diphenylether; octabromo derivate; ethylene thiourea; methyl
isocyanate; N-ethyl-2-pyrrolidone; nitrobenzene; phenol, (tetrapropenyl) derivatives; phenol, 2-dodecyl-, branched; phenol, 3-dodecyl-, branched; phenol,
4-dodecyl-, branched; phenol, dodecyl-, branched; p-phenylenediamine; R-glycidol; thiourea; trixylyl phosphate
Phthalates
(n = 13)
1,2-benzenedicarboxylic acid; 1,2-benzenedicarboxylic acid, dipentylester, branched and linear; benzyl butyl phtalate; bis(2-ethylhexyl) phthalate; bis(2-methoxyethyl)





ammonium nonadecafluorodecanoate; ammonium perfluorooctane sulfonate; ammoniumpentadeca- fluorooctanoate; diethanolamine perfluorooctane sulfonate; lithium
perfluorooctane sulfonate; nonadecafluorodecanoic acid; perfluorononan-1-oic acid; perfluorononan-1-oic acid ammonium salts; perfluorononan-1-oic acid sodium salts;
perfluorooctane sulfonic acid; perfluorooctanoic acid; potassium perfluorooctanesulfonate; sodium nonadecafluorodecanoate
Other compounds
(n = 26)
Bisphenols (n = 2)
bisphenol A; 4,4-isobutylethylidenediphenol
Chelating agent (n = 2)
quinolin-8-ol; EDTA
Oxides of carbon (n = 1)
carbon monoxide
Hydrocarbons (n = 2)
benzo[a]pyrene; pitch, coal tar, high-temp.
Other compounds (n = 19)
(dimethylamino)thioacetamide hydrochloride[6,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6-oxo-1H-purin-2-yl]acetamide; 1,2-benzenedicarboxylic acid,





chloro-N,N-dimethylformiminium chloride; cyclic 3-(1,2-ethanediylacetale)-estra-5(10),9(11)-diene-3,17-dione; methyl-ONN-azoxymethyl acetate; potassium
1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate
reaction mass of: 1,3,5-tris(3-aminomethylphenyl)-1,3,5-(1H,3H,5H)-triazine-2,4,6-trione; reaction mass of: 4-[[bis-(4-fluorophenyl)methylsilyl]methyl]-4H-1,2,4-triazole;
reaction mass of: disodium
4-(3-ethoxycarbonyl-4-(5-(3-ethoxycarbonyl-5-hydroxy-1-(4-sulfonatophenyl)pyrazol-4-yl)penta-2,4-dienylidene)-4,5-dihydro-5-oxopyrazol-1-yl)benzenesulfonate;
tetrahydrothiopyran-3-carboxaldehyde; tris(2-chloroethyl)phosphate
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4. Discussion
4.1. Main Findings
Our method allowed us to identify 1251 environmental reproductive hazards from two regulatory
lists and four health agency scientific reports or databases. Our prioritization approach resulted in a
high-priority classification for 462 risk factors. These substances belong to the following eight classes
of chemicals: drugs (n = 206), metals and metalloids (n = 116), pesticides (n = 38), organic solvents
(n = 27), synthesizing and/or processing agents in industrial processes (n = 23), phthalates (n = 13),
perfluorinated compounds (n = 13), and other compounds (n = 26).
4.2. Strengths and Weaknesses
Our method enabled us to establish a relatively exhaustive list of risk factors, more complete than
the classifications considered separately. Notably, we identified more reproductive hazards than those
registered on the regulatory lists. Indeed, the classifications we used were established for various
reasons and therefore cover various fields. For example, the CLP regulation applies to substances and
mixtures supplied to the community but excludes drugs, which are included in the Proposition 65 and
NIOSH lists.
We identified a large number of reproductive hazards (n = 1251). One strength of our method
was the prioritization of the risk factors, based on the weight of the available scientific evidence,
to determine their negative effects on reproductive health. Indeed, it is essential that clinical practice is
based on the available scientific data to propose adequate and risk-proportionate preventive measures.
The principal limitation of our study was that the classifications we used do not necessarily reflect
our clinical objective. They often omit complex mixtures, substances unintentionally generated by
industrial processes, and/or prohibited chemicals. However, in the latter case, these substances can be
relevant to our approach, because they persist in the environment and can lead to exposure.
In addition, some risk factors cannot be registered, despite scientific evidence of an adverse impact
on reproduction in the scientific literature because of the time that is required for scientific expertise,
although the lists are generally updated on a regular basis.
These two limitations can result in the non-identification of relevant risk factors or an unfavorable
ranking of the substances in a lower category than they should be. For example, tobacco smoke is
only registered on the Proposition 65 list and is ranked on our list as a Category 3 low-priority risk
factor. However, there is sufficient published data to confirm the deleterious effects, which promote
adverse pregnancy outcomes in humans [3,4,18]. Consequently, we should prioritize tobacco smoke as
a high-priority risk factor (Category 1).
These lists should thus be completed by a bibliographic or expert review. Positive scientific
evidence in publications should allow for the identification of new risk factors or reclassification to a
higher priority level. This approach implies a chemical-by-chemical evaluation, such as that developed
in other fields by independent organizations, such as the International Agency for Research on Cancer
(IARC). Thus, one of the IARC’s missions is to classify agents based on their potential carcinogenicity
according to the available evidence to guide cancer prevention.
Another example is given by the “Navigation Guide Systematic Review Methodology”,
a systematic and transparent review that has been developed in the environmental health field to aid
government agencies, professional societies, and healthcare organizations in improving the outcome
of patients and, ultimately, the general health of the population [19]. However, this approach is time
consuming and requires human resources that are not currently available.
Another possibility would be to incorporate more existing classifications. We cannot exclude
the existence of additional scientific studies, especially national studies that may have not been
included in this study. However, we chose to exclude substances or mixtures not registered in Annex
VI to the CLP that nevertheless concerned by self-classification. Indeed, we based our analysis on
validated and harmonized data to ensure adequate risk management. However, we could have
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included some of these chemicals, hence assigning them a low level of evidence. However, according
to the Classification and Labelling Inventory database available on the ECHA website, a total of 4699
substances are classified as reprotoxic (R1A, R1B, or R2). There are also 924 substances classified as a
mutagen (M1A, M1B, or M2). This information can be taken into account on a case-by-case basis in
clinical practice by consulting the ECHA website [20].
4.3. Findings in Relation to Other Studies
Much of the scientific literature on the identification of reproductive risk factors is composed of
reviews of epidemiological studies and/or toxicological data [2–5]. These analyses often concern a
limited number of risk factors that partially match those on our list. We found two studies, which
identified chemicals with reprotoxic properties, prioritized on the basis of the estimated exposure of
the general [21] or worker population [22].
Some classes of chemicals of the highest concern are also included in our list of high-priority risk
factors, such as phthalates, metals, alkylphenols, and glycol ethers [21]. Hence, practitioners should be
vigilant concerning patient exposure to these risk factors in clinical practice.
However, other chemicals were not included (such as drugs) or not classed according to the
same priority ranking. These differences can be explained by various factors, including the use of
different scientific sources for the identification of the risk factors, a possible update of the lists in
common, and divergence in the prioritization approaches. Indeed, we prioritized the substances based
on the weight of the evidence of reprotoxic effects, whereas the other studies calculated a score based
on exposure.
4.4. Implications and Perspectives
Our method was developed to identify and prioritize environmental reproductive hazards
according to science-based information. Thus, we now have a list of risk factors of interest, ranked by
current scientific concern. However, these lists cannot be directly used by perinatal health professionals
in assessing patient exposure to reproductive factors. Nevertheless, this exercise represents a first
step in establishing innovative environmental perinatal care. Indeed, assessment of the risk on
reproductive health and the application of proportional preventive measures will require crossing
information concerning the hazard related to a substance with the cumulative level of occupational
and/or non-occupational exposure. This demands specialized skills, and it may be difficult for
health professionals to link such risks with environmental exposure circumstances by themselves.
Indeed, several studies in France and other countries have reported difficulties for perinatal health
professionals to properly inform their patients in their regular practice about environmental risks.
A lack of training and knowledge in environmental health, the lack of evidence-based information,
and the short duration of consultations were the most frequently cited difficulties [6,7].
These elements favor the development of dedicated tools and medical structures to assist health
professionals in this environmental health approach. One example is the Bordeaux University
Medical Center, which has a specialized center dedicated to the evaluation of environmental risks
on reproductive health, called the “Centre ARTEMIS” [23]. In this context, a specialized interview
guide has been developed in order to detect the environmental exposure circumstances to reproductive
hazards during consultations. Then, several prevention-oriented measures are proposed, depending on
the priority category of the risk factor detected and the level of exposure: elimination of the risk factor
from the patient’s environment, mitigation of the risk by proposing collective and individual protective
equipment in an occupational setting, and changing attitudes concerning household practices (reasoned
choice of products, aeration, etc.). At the same time, reproductive health professionals receive
information concerning patient exposure, allowing the incorporation of environmental health in
global medical care and progressive training of the perinatal health providers.
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5. Conclusions
Our method allowed us to identify 1251 environmental reproductive hazards from existing
classifications. Our prioritization approach resulted in the high-priority classification of 462
reproductive risk factors, grouped in eight classes. Exposure to these families should be given priority
by perinatal health providers during patient interviews. We also identified 79 reproductive hazards
with a medium-priority classification and 710 substances or mixtures with a low-priority ranking.
It would be informative to complete this work with a bibliographic or expert review to address the
inherent limits of our methodology and add robustness to the study. Nonetheless, the generated
lists constitute a useful working basis to put in place innovative environmental preventive measures
according to the principle evidence-based medicine.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-4601/16/3/366/s1,
Table S1: Full list of environmental chemical hazards on reproduction.
Author Contributions: R.T., P.B., and F.D. developed the method to identify and prioritize the environmental
reproductive hazards. R.T. wrote the article. All the authors have read and approved the final manuscript.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflicts of interest.
References
1. Di Renzo, G.C.; Conry, J.A.; Blake, J.; DeFrancesco, M.S.; DeNicola, N.; Martin, J.N.; McCue, K.A.;
Richmond, D.; Shah, A.; Sutton, P.; et al. International Federation of Gynecology and Obstetrics opinion on
reproductive health impacts of exposure to toxic environmental chemicals. Int. J. Gynaecol. Obstet. Off. Organ
Int. Fed. Gynaecol. Obstet. 2015, 131, 219–225. [CrossRef] [PubMed]
2. Gabrielsen, J.S.; Tanrikut, C. Chronic exposures and male fertility: The impacts of environment, diet, and
drug use on spermatogenesis. Andrology 2016, 4, 648–661. [CrossRef] [PubMed]
3. Stillerman, K.P.; Mattison, D.R.; Giudice, L.C.; Woodruff, T.J. Environmental exposures and adverse
pregnancy outcomes: A review of the science. Reprod. Sci. 2008, 15, 631–650. [CrossRef] [PubMed]
4. Slama, R.; Cordier, S. Impact of chemical and physical environmental factors on the course and outcome of
pregnancy. J. Gynecol. Obstet. Biol. Reprod. (Paris) 2013, 42, 413–444. [CrossRef] [PubMed]
5. Vrijheid, M.; Casas, M.; Gascon, M.; Valvi, D.; Nieuwenhuijsen, M. Environmental pollutants and child
health—A review of recent concerns. Int. J. Hyg. Environ. Health 2016, 219, 331–342. [CrossRef] [PubMed]
6. Stotland, N.E.; Sutton, P.; Trowbridge, J.; Atchley, D.S.; Conry, J.; Trasande, L.; Gerbert, B.; Charlesworth, A.;
Woodruff, T.J. Counseling patients on preventing prenatal environmental exposures—A mixed-methods
study of obstetricians. PLoS ONE 2014, 9, e98771. [CrossRef] [PubMed]
7. Marie, C.; Lémery, D.; Vendittelli, F.; Sauvant-Rochat, M.-P. Perception of Environmental Risks and Health
Promotion Attitudes of French Perinatal Health Professionals. Int. J. Environ. Res. Public. Health 2016, 13,
1255. [CrossRef] [PubMed]
8. Genuis, S.J. Health issues and the environment—An emerging paradigm for providers of obstetrical and
gynaecological health care. Hum. Reprod. 2006, 21, 2201–2208. [CrossRef] [PubMed]
9. Windham, G.; Fenster, L. Environmental contaminants and pregnancy outcomes. Fertil. Steril. 2008, 89,
e111–e116. [CrossRef] [PubMed]
10. European Parliament and Council of the European Union. Regulation (EC) No 1272/2008 of the European
Parliament and of the Council of 16 December 2008 on Classification, Labelling and Packaging of Substances and
Mixtures, Amending and Repealing Directives 67/548/EEC and 1999/45/EC, and Amending Regulation (EC) No
1907/2006; OJ L 353, 31.12.2008; European Parliament and Council: Brussels, Belgium, 2008; pp. 1–1355.
11. Connor, T.; MacKenzie, B.; DeBord, D.; Trout, D.; O’Callaghan, J.; Cincinnati, O. CDC—NIOSH Publications
and Products—NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016 (2016-161);
NIOSH: Washington, DC, USA, 2017.
12. Jahnke, G.D.; Iannucci, A.R.; Scialli, A.R.; Shelby, M.D. Center for the evaluation of risks to human
reproduction—The first five years. Birth Defects Res. B Dev. Reprod. Toxicol. 2005, 74, 1–8. [CrossRef] [PubMed]
Int. J. Environ. Res. Public Health 2019, 16, 366 14 of 14
13. Demeter. Available online: http://www.inrs.fr/dms/inrs/PDF/bdd-demeter/DemeterGuideDeLecture/
DemeterGuideDeLecture.pdf (accessed on 3 April 2018).
14. Groshart, C.; Okkerman, P.C. Towards the Establishment of a Priority List of Substances for Further Evaluation
of Their Role in Endocrine Disruption: Preparation of a Candidate List of Substances as a Basis for Priority Setting;
Final Report (Incorporating Corrigenda to Final Report Dated 21 June 2000); BKH Consulting Engineers:
Delft, The Netherlands; TNO Nutrition and Food Research: Zeist, The Netherlands, 2000; p. 29.
15. Office of Environmental Health Hazard Assessment (OEHHA). State of California Environmental Protection
Agency Office of Environmental Health Hazard Assessment Safe Drinking Water and Toxic Enforcement Act of 1986
Chemicals Known to the State to Cause Cancer or Reproductive Toxicity; Office of Environmental Health Hazard
Assessment (OEHHA): Sacramento, CA, USA, 2017.
16. Okkerman, P.C.; van der Putte, I. Endocrine Disrupters: Study on Gathering Information on 435 Substances with
Insufficient Data; RPS BKH Consulting Engineers: Delft, the Netherlands, 2002; p. 52.
17. Petersen, G.; Rasmussen, D.; Gustavson, K. Study on Enhancing the Endocrine Disrupter Priority List with a
Focus on Low Production Volume Chemicals; DHI Water and Environment: Hørsholm, Denmark, 2007; p. 52.
18. Pineles, B.L.; Park, E.; Samet, J.M. Systematic review and meta-analysis of miscarriage and maternal exposure
to tobacco smoke during pregnancy. Am. J. Epidemiol. 2014, 179, 807–823. [CrossRef] [PubMed]
19. Woodruff, T.J.; Sutton, P. The Navigation Guide systematic review methodology: A rigorous and transparent
method for translating environmental health science into better health outcomes. Environ. Health Perspect.
2014, 122, 1007–1014. [CrossRef] [PubMed]
20. Information on Chemicals—ECHA. Available online: https://echa.europa.eu/information-on-chemicals
(accessed on 12 January 2018).
21. Bonvallot, N.; Mullot, J.-U.; Solal, C.; Dor, F. Méthode d’identification et de hiérarchisation des substances
reprotoxiques pour la construction de valeurs toxicologiques de référence. Environ. Risques Santé 2009, 8,
119–131.
22. Moorman, W.J.; Ahlers, H.W.; Chapin, R.E.; Daston, G.P.; Foster, P.M.; Kavlock, R.J.; Morawetz, J.S.;
Schnorr, T.M.; Schrader, S.M. Prioritization of NTP reproductive toxicants for field studies. Reprod. Toxicol.
2000, 14, 293–301. [CrossRef]
23. Delva, F.; Coquet, S.; Manangama, G.; Teysseire, R.; Brochard, P.; Sentilhes, L. The Artemis Center:
An environmental health platform dedicated to reproduction, Bordeaux (France). Report of the First
Year of Activity 2016–2017. Bull. Epidémiol Hebd. 2018, 22–23, 486–492.
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
